Influence of trastuzumab on the incidence of brain metastasis in patients with Her2-overexpressing metastatic breast cancer

被引：0
|
作者：
Massard, C.
Brain, E.
Dunan, A.
Mathieu, M.
Guinebretiere, J.
Abuin, G. Gomez
Floiras, J.
Spielmann, M.
Delaloge, S.
Andre, F.
机构：
[1] Inst Gustave Roussy, Breast Canc Unit, Villejuif, France
[2] Ctr Rene Huguenin, Dept Med, St Cloud, France
[3] Inst Gustave Roussy, Dept Stat, F-94805 Villejuif, France
[4] Inst Gustave Roussy, Dept Pathol, Villejuif, France
[5] Ctr Rene Huguenin, Dept Pathol, St Cloud, France
[6] Ctr Rene Huguenin, Dept Radiat Therapy, St Cloud, France
来源：
EJC SUPPLEMENTS | 2005年 / 3卷 / 02期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：119 / 120
页数：2
相关论文
共 50 条
  • [21] Phase II study of pertuzumab, trastuzumab, and weekly paclitaxel in patients with HER2-overexpressing metastatic breast cancer (MBC).
    Datko, Farrah Mikhail
    D'Andrea, Gabriella
    Dickler, Maura N.
    Goldfarb, Shari Beth
    Theodoulou, Maria
    Lake, Diana
    Fornier, Monica Nancy
    Modi, Shanu
    Fasano, Julie
    Comen, Elizabeth Anne
    Gajria, Devika
    Moynahan, Mary Ellen
    Traina, Tiffany A.
    Chen, Melanie
    Hamilton, Nicola
    Patil, Sujata
    Chandarlapaty, Sarat
    Hudis, Clifford
    Dang, Chau T.
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
  • [22] Capecitabine combined with trastuzumab in the therapy of intensively pretreated HER2-overexpressing metastatic breast cancer (MBC).
    Bangemann, N
    Kuhle, A
    Ebert, A
    Bühler, H
    Schaller, G
    ANNALS OF ONCOLOGY, 2000, 11 : 143 - 143
  • [23] Application of intrathecal trastuzumab (Herceptin™) for treatment of meningeal carcinomatosis in HER2-overexpressing metastatic breast cancer
    Stemmler, HJ
    Schmitt, M
    Harbeck, N
    Willems, A
    Bernhard, H
    Lässig, D
    Schoenberg, S
    Heinemann, V
    ONCOLOGY REPORTS, 2006, 15 (05) : 1373 - 1377
  • [24] Brain metastases in HER2-overexpressing metastatic breast cancer: Comparative analysis of trastuzumab levels in serum and cerebrospinal fluid.
    Stemmler, J.
    Schmitt, M.
    Willems, A.
    Bernhard, H.
    Harbeck, N.
    Heinemann, V.
    JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (18) : 64S - 64S
  • [25] Characteristics of patients with brain metastases receiving trastuzumab for HER2 overexpressing metastatic breast cancer
    Stemmler, H. J.
    Kahlert, S.
    Siekiera, W.
    Untch, M.
    Heinrich, B.
    Heinemann, V.
    BREAST, 2006, 15 (02): : 219 - 225
  • [26] Trastuzumab (Herceptin®): overcoming resistance in HER2-overexpressing breast cancer models
    Albrecht, Huguette
    IMMUNOTHERAPY, 2010, 2 (06) : 795 - 798
  • [27] Combined neoadjuvant weekly paclitaxel and trastuzumab for HER2-overexpressing breast cancer
    Horiguchi, J.
    Koibuchi, Y.
    Rokutanda, N.
    Nagaoka, R.
    Kikuchi, M.
    Sato, A.
    Ishikawa, Y.
    Odawara, H.
    Iino, Y.
    Takeyoshi, I.
    JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (18)
  • [28] Effect of dasatinib on the activity of trastuzumab in HER2-overexpressing breast cancer cells
    Seoane, S.
    Montero, J. C.
    Pandiella, A.
    Ocana, A.
    JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (15)
  • [29] Trastuzumab plus GM-CSF for patients with trastuzumab-resistant, HER2-overexpressing metastatic breast cancer: Pilot study.
    Ueno, NT
    Rondon, G
    Williams, P
    Champlin, RE
    Murray, JL
    Cristofanilli, M
    Royce, M
    Walter, RB
    Theriault, RL
    Hortobagyi, GN
    Valero, V
    JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (16) : 78S - 78S
  • [30] Trastuzumab treatment improves brain metastasis outcomes through control and durable prolongation of systemic extracranial disease in HER2-overexpressing breast cancer patients
    Park, Y. H.
    Park, M. J.
    Ji, S. H.
    Yi, S. Y.
    Lim, D. H.
    Nam, D. H.
    Lee, J-I
    Park, W.
    Choi, D. H.
    Huh, S. J.
    Ahn, J. S.
    Kang, W. K.
    Park, K.
    Im, Y-H
    BRITISH JOURNAL OF CANCER, 2009, 100 (06) : 894 - 900
12345